The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Open accessAbstract
BACKGROUND: Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, binds to low-density lipoprotein (LDL) receptors, leading to their accelerated degradation and to increased LDL cholesterol levels. We report three phase 1 studies of a monoclonal antibody to PCSK9 designated as REGN727/SAR236553 (REGN727). METHODS: In healthy volunteers, we performed two randomized, single ascending-dose studies of REGN727 administered either intravenously (40 subjects) or subcutaneously (32 subjects), as compared with placebo. These studies were followed by a randomized, placebo-controlled, multiple-dose trial in adults with heterozygous familial hypercholesterolemia who were receiving atorvastatin (21 subjects) and those with nonfamilial hypercholesterolemia who were receiving treatment with atorvastatin (30 subjects) (baseline LDL cholesterol, >100 mg per deciliter [2.6 mmol per liter]) or a modified diet alone (10 subjects) (baseline LDL cholesterol, >130 mg per deciliter [3.4 mmol per liter]). REGN727 doses of 50, 100, or 150 mg were administered subcutaneously on days 1, 29, and 43. The primary outcome for all studies was the occurrence of adverse events. The principal secondary outcome was the effect of REGN727 on the lipid profile. RESULTS: Among subjects receiving REGN727, there were no discontinuations because of adverse events. REGN727 significantly lowered LDL cholesterol levels in all the studies. In the multiple-dose study, REGN727 doses of 50, 100, and 150 mg reduced measured LDL cholesterol levels in the combined atorvastatin-treated populations to 77.5 mg per deciliter (2.00 mmol per liter), 61.3 mg per deciliter (1.59 mmol per liter), and 53.8 mg per deciliter (1.39 mmol per liter), for a difference in the change from baseline of -39.2, -53.7, and -61.0 percentage points, respectively, as compared with placebo (P<0.001 for all comparisons). CONCLUSIONS: In three phase 1 trials, a monoclonal antibody to PCSK9 significantly reduced LDL cholesterol levels in healthy volunteers and in subjects with familial or nonfamilial hypercholesterolemia. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT01026597, NCT01074372, and NCT01161082.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y.-A., & Horton, J. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501652102 · Cited by 679
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L. N., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 642
Maxwell, K. N., & Breslow, J. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402133101 · Cited by 613
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517
Park, S. W., Moon, Y.-A., & Horton, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410077200 · Cited by 452
Chan, J. C. Y., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903849106 · Cited by 371
Research works printed but not linked: 1
- Olsson AG, 2001, Clin Cardiol, 24, III
Cited by
Sorted by citations
Items 601–665 of 665
Current challenges in the management of patients with familial hypercholesterolemia
Arca, M., Salvia, E., & Pigna, G. (2013) · Clinical Lipidology · doi:10.2217/clp.13.12
CETP Pharmacological Manipulation Transforming Human into Mouse: Is this Still a Viable Hypothesis?
Morales-Villegas, E., Moreno-Virgen, G., & Barter, P. J. (2012) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152212803521057
Sun, H. (2012) · Digital Commons-TMC (Texas Medical Center)
Proprotein convertase subtilisin/kexin type 9 related familial hypercholesterolaemia
Hanton, S. L., & van Heyningen, C. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412463256
Neue Entwicklungen in der Lipidtherapie
Parhofer, K. G. (2012) · Der Diabetologe · doi:10.1007/s11428-012-0892-3
New targets and developments in lipoproteins control
Norata, G. D. (2013) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s34904
Genetics of Coronary Artery Disease
Fuster, V., & Kovacic, J. C. (2014)
T-cell specificity and regulation in atherosclerosis
Gisterå, A. (2015) · Figshare
Chu, G. (2015) · uO Research (University of Ottawa) · doi:10.20381/ruor-1435
Regulation of cholesterol metabolism: An IDOL-dependent pathway to degrade the LDL-receptor
Sorrentino, V. (2014) · UvA-DARE (University of Amsterdam)
A potential role for monoclonal antibodies in clinical lipidology
Kalhan, A., & Rees, A. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283654f27
Chowdhury, S. R., & Rees, A. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328358246a
From statin efficacy to everyday effectiveness: Studying the gap in between.
Ruokoniemi, P. T. (2015) · UTUPub (University of Turku)
Aronow, W. S. (2013) · doi:10.2217/fmeb2013.13.81
(2016) · Journal of Cardiology & Current Research · doi:10.15406/jccr.2016.07.00235
Hipercolesterolemia familiar heterocigota en manejo con anti–PCSK9
Duque, M., Gaviria, M. C., González, J., & Gallo, J. E. (2017) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2017.03.002
Estudios clínicos con inhibidores de la PCSK9
Campo, R. (2017) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2017.08.019
Dreaming of the future of stroke: translation of bench to bed
Bang, O. Y., Chang, W. H., & Won, H. (2017) · Precision and Future Medicine · doi:10.23838/pfm.2017.00163
PCSK9 inhibition: drug development for low-density lipoprotein lowering
Mukerji, G., Abdin, R., & Ng, D. S. (2013) · doi:10.2217/fmeb2013.13.21
SGLT1 and Sweet Genetic Insights Into Cardiometabolic Risk
Ahmad, F., Zhao, L., & Shibbani, K. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.060
Treating hypercholesterolaemia with evolocumab
Češka, R., Šnejdrlová, M., Vrablı́k, M., Altschmiedová, T., & Štulc, T. (2018) · Intervenční a akutní kardiologie · doi:10.36290/kar.2018.057
Research: Clinical, Basic, and Translational
Cokkinos, D. V. (2019) · Springer eBooks · doi:10.1007/978-3-319-98186-4_2
Ozaki, K., & Tanaka, T. (2019) · Springer eBooks · doi:10.1007/978-981-13-8177-5_2
PCSK9 and LDL-C: The Role of Exercise
Jin, J., Jo, W., Noh, J. H., & Lee, S. K. (2020) · Exercise Science · doi:10.15857/ksep.2020.29.4.347
GOLIATH regulates LDLR availability and plasma LDL cholesterol levelsPreprint
Clifford, B. L., Jarrett, K. E., Cheng, J., Cheng, A., Seldin, M. M., Morand, P., Lee, R. E., Jr., Baldán, Á., Vallim, T. Q. D. A., & Tarling, E. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.09.415323
Genetic and lifestyle risks of cardiovascular disease
Said, M. A. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.157192207
Faculty Opinions recommendation of Effect of alirocumab on mortality after acute coronary syndromes.
Aronow, W. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735819386.793563697
Devasani, K., Majumdar, A. S., Jhonsa, D., & Kaul, R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.20.485060
Zhang, Q., Deng, L., Chen, C., Pan, X., & Jiang, S. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2021.0109
Research Progress of Application of Novel Li-pid-Regulating Drugs
商, 博. (2018) · Pharmacy Information · doi:10.12677/pi.2018.74014
PCSK9-Hemmer: Können sie kardiovaskuläre Ereignisse verhindern?
DE (2015) · CardioVasc · doi:10.1007/s15027-015-0635-7
Iqbal, O., Syed, D., & Fareed, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_220-1
4th Asian Preventive Cardiology And Cardiac Rehabilitation Conference
(2012) · Journal of the Hong Kong College of Cardiology · doi:10.55503/2790-6744.1052
Liu, M., & Rader, D. J. (2015) · Atherosclerosis · doi:10.1002/9781118828533.ch1
Research Progress of Inclisiran
王, 玉. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.1281061
Fujino, M., & Nicholls, S. J. (2023) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2023.3.e14
Haverich, A., & Boyle, E. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-31766-8_2
Pediatric Preventive Cardiology
Ward, K. M., Greco, M. M., Peterson, A. L. H., Matossian, D., & Benuck, I. (2023) · Springer eBooks · doi:10.1007/978-3-030-42937-9_107-1
Turner, F. R. T., & Stein, E. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00030-x
Self-citationExercise and Improvement of LDL-C via PCSK9
Lee, S. K. (2024) · Exercise Science · doi:10.15857/ksep.2024.00297
Special focus on the new anti-diabetic drugs
Agewall, S. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae039
Challenges in the management of familial hypercholesterolemia: a case report
Rogozik, J. K., Grabowski, M., & Główczyńska, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1417432
O USO DE INIBIDOR PCSK9 PARA CONTROLE DE DISLIPIDEMIA E SUA AÇÃO EM DOENÇAS CARDIOVASCULARES
MOREIRA, M. G. D. S., FURTADO, J. B. D. S., Schaffazick, F., RITTER, R. S., ASSUNÇÃO, G. L., PEREIRA, M. E., & FURTADO, L. B. F. D. S. (2025) · Editora Pasteur eBooks · doi:10.59290/978-65-6029-248-2.3
PCSK9 in critical illness – It’s not all about lipids
Crossley, E., Silversides, J. A., O’Kane, C. M., & Hamilton, P. (2025) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632251395579
Ahmad, Z., & Garg, A. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_30
Shu, Y., Deng, Z., Deng, Y., Zhou, J., Wang, J., Duan, Z., Jiang, T., Zhao, X., Shi, Z., & Qiu, C. (2023) · Figshare · doi:10.6084/m9.figshare.24465082
Shu, Y., Deng, Z., Deng, Y., Zhou, J., Wang, J., Duan, Z., Jiang, T., Zhao, X., Zhihua, S., & Qiu, C. (2024) · Figshare · doi:10.6084/m9.figshare.24465342
刘, 美. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15113273
Functional impact of PCSK9 variants on LDL uptake in a knockout hepatic model
Li, H., Liu, H., Xu, W., Zeng, Y., Huang, P., Guo, J., Cai, B., Chen, Y., Lin, Y., & Zhang, C. (2026) · PLoS ONE · doi:10.64898/2026.03.13.711724
Mudla, A., Quintana, D. D., Atallah, C. F., Savoy, L. R., Leu, A. I., Dam, T., Acharya, G., Rajappan, K., & Chivukula, P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.20.713290
Hypercholestérolémie familiale : recherche de nouveaux gènes et étude des formes polygéniques
Ghaleb, Y. (2017) · theses.fr (ABES) · doi:10.70675/ab0b16eez4c40z4cb7zb42fzb7740e0c98ea
Approches biochimique, épidémiologique et clinique du métabolisme intégré de la Lipoprotéine (a)
Blanchard, V. (2020) · theses.fr (ABES) · doi:10.70675/3ce7e0fdzecbaz4b18zaf08z34fb33c163ff
Le rôle du récepteur aux LDL et de PCSK9 dans le diabète de type 2
Ramin‐Mangata, S. (2020) · theses.fr (ABES) · doi:10.70675/26622ba5zb0fcz4d30za6e6z5c95a0b5a33d
Chemello, K. (2022) · theses.fr (ABES) · doi:10.70675/6f647f12za09bz494fzae02z9be71ebf2915
The role of PCSK9 in cancer risk: Population-level evidence and mechanistic insights
Liu, H., Zhou, T., Wang, L., Liu, F., & Gu, D. (2026) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000141
Ding, W., Liu, Q., Luo, Q., Yao, X., & Fan, X. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71304
CRISPR therapy for dyslipidemia
Nicholls, S. J. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001062 · Cited by 1
BindingDB (2021) · UC San Diego · doi:10.7270/q2j38wzz
Metadata
- Authors
- Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., Du, Y., Kranz, T., Gasparino, E., & Swergold, G. D.
- Affiliations
- Regeneron (United States) (US)
- Medpace (United States) (US)
- University of Tennessee Medical Center (US)
- IQVIA (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-22
- Volume
- 366
- Issue
- 12
- Pages
- 1108-1118
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989730880
- Semantic Scholar
- 04c1ea8c55c4bae0da3106e47141bac81e1bb585
- Cited by
- 664
- References
- 15
- Citations by year
- 2026: 12 · 2025: 11 · 2024: 29 · 2023: 22 · 2022: 19 · 2021: 20 · 2020: 38 · 2019: 29 · 2018: 46 · 2017: 58 · 2016: 62 · 2015: 86 · 2014: 83 · 2013: 92 · 2012: 57
- FWCI
- 103.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- PCSK9, monoclonal antibodies, LDL cholesterol, LDL receptor degradation, hypercholesterolemia, familial hypercholesterolemia, atorvastatin, lipid profile, adverse events, dose escalation, cholesterol absorption inhibition
- MeSH terms
- Atorvastatin, Proprotein Convertase 9, Adult, Antibodies, Monoclonal, Anticholesteremic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Hyperlipoproteinemia Type II, Injections, Intravenous, Injections, Subcutaneous, Lipoproteins, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Receptors, LDL, Serine Endopeptidases, Least-Squares Analysis, Proprotein Convertases, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
